Wednesday 27 September 2023 - 01:32
NOTE: all of our usual telephone and FAX systems are currently down due to a dispute between our landlord and Verizon. We are working to remedy this situation and get our phones back on ASAP.
In the meantime, please use this mobile phone number: 978-715-9327, and this fax number: 781-491-0695.
Thank you for your patience as we work through this unfortunate outage caused by a dispute beyond our control.
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
D-8147 Duvelisib, Free Base, >99%
Synonyms : [IPI-145] [INK-1197]
Related Terms : [Copiktra]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 49
- 46
- 40
- 7,300
- In stock
- 10 mg
- 75
- 70
- 61
- 11,200
- In stock
- 25 mg
- 119
- 112
- 97
- 17,700
- In stock
- 50 mg
- 162
- 152
- 132
- 24,100
- In stock
- 100 mg
- 218
- 205
- 178
- 32,500
- In stock
- 200 mg
- 359
- 338
- 294
- 53,400
- In stock
- 500 mg
- 722
- 680
- 592
- 107,500
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 416.86
- C22H17ClN6O
- [1201438-56-3]
- Duvelisib, also known as IPI-145, is a potent inhibitor of phosphoinositide-3-kinase (PI3K) [delta] and PI3K [gamma]. It inhibits PI3K [delta] and [gamma] with Ki values of 23 and 243 pM, cell-free IC50 values of 2.5 and 27.4 nM, and cellular IC50 values of 1 nM and 43 nM, respectively. It was active in preclinical models of arthritis. Porter J.R., et al. "The potent phosphoinositide-3-kinase-(delta, gamma) inhibitor IPI-145 is active in preclinical models of arthritis and well tolerated in healthy adult subjects." http://infi.com/pdfs/ACR_ARHP2012.pdf
- Duvelisib was active and well-tolerated in patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas. Horwitz S., et al. "Preliminary Safety and Efficacy of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ, γ in Patients with Relapsed/Refractory T-Cell Lymphoma." http://infi.com/pdfs/LuganoTcell.pdf
- A phase I trial demonstrated that duvelisib was well tolerated and showed initial clinical activity in patients with indolent non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. Flinn I.W., et al. "Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, in Patients with Advanced Hematologic Malignancies." Blood (ASH Annual Meeting Abstracts) 120: Abstract 3663 (2012).
- Other CAS numbers previously assigned to IPI-145 free base, namely 1355213-59-0 and 1428465-12-6, have been deleted by CAS and are no longer in use.
- Duvelisib is the active ingredient in the drug product sold under the trade name Copiktra®. This drug is currently approved in at least one country for the treatnent of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. NOTE: THE DUVELISIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT COPIKTRA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.